Pipeline

Commercialized Products

TAVALISSE® (fostamatinib)1

Adult Chronic Immune Thrombocytopenia (ITP)
Target: Spleen tyrosine kinase (SYK)

Pre-Clinical Phase 1 Phase 2 Phase 3 Approved
Pre-Clinical Complete
Phase 1 Complete
Phase 2 Complete
Phase 3 Complete
Approved Complete

REZLIDHIA® (olutasidenib)2

R/R Acute Myeloid Leukemia
Target: Mutant isocitrate dehydrogenase–1 (mIDH1)

Pre-clinical Phase 1 Phase 2 NDA FILED Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
NDA FILED Complete
Approved Complete

Clinical Trials

R289*

LR-MDS
Target: Interleukin receptor-associated kinases 1 and 4 (IRAK1/4)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Not Started
Phase 3 Not Started
Approved Not Started

Partnered Programs

Milademetan* - Daiichi Sankyo

Liposarcoma
Target: Murine double minute 2 (MDM2)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
Phase 3 Complete
Approved Not Started

Fostamatinib* – ACTIV4 Host Tissue3

COVID-19
Target: Spleen tyrosine kinase (SYK)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
Phase 3 In Progress
Approved Not Started

Bemcentinib* - BerGenBio

NSCLC & COVID-19
Target: AXL receptor tyrosine kinase (AXL)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 In Progress
Phase 3 Not Started
Approved Not Started

R552* (Systemic) – Eli Lilly

Rheumatoid Arthritis
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 In Progress
Phase 3 Not Started
Approved Not Started

Rxxx (CNS penetrant) – Eli Lilly

CNS Diseases
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical In Progress
Phase 1 Not Started
Phase 2 Not Started
Phase 3 Not Started
Approved Not Started

KEY:

Company-sponsored Trials Select Investigator-sponsored Trials Partnered Programs

1 Please see the TAVALISSE Full Prescribing Information

2 Please see the REZLIDHIA Full Prescribing Information, including Boxed WARNING

3 Coordinated by Vanderbilt University Medical Center and funded by National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)

* Investigational compounds in these indications have not been submitted for FDA review